Ablynx extends ion channel research collaboration with Merck & Co.
Ablynx announced an extension of its initial two-year research collaboration with Merck & Co., Inc., known as MSD outside the United States and Canada, to develop and commercialise Nanobody® candidates directed towards an undisclosed voltage gated ion channel.
Merck & Co., Inc. will extend their funding of the research collaboration with Ablynx to the end of September 2016. This ion channel collaboration was announced in October 2012 and included a €6.5 million upfront payment and €2 million in initial research funding.
Merck and Ablynx have a separate collaboration in the field of cancer immuno-therapy, announced in February in 2014, with a €20 million upfront payment, €10.7 million in research funding and total potential milestone payments of up to €1.7 billion plus royalties.
Most read news
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Biositemap
Faulty clean-up process may be key event in Huntington's disease
Cardio3 BioSciences Reports Positive Three-Month Data from its Clinical Trial of C-Cure in Heart Failure
UCLA researchers discover new molecular pathway for targeting cancer, disease

A molecular machine at work - Researchers unravel the assembly of an enzyme that detoxifies the greenhouse gas N₂O
How one strain of MRSA becomes resistant to last-line antibiotic
Ablynx Successfully Generates Nanobodies Against an Ion Channel and Announces New GPCR Programme
Emotional_Freedom_Techniques
Santhera Announces Intent To File Marketing Authorization Application for Leber's Hereditary Optic Neuropathy
Janssen-Cilag International NV withdraws its application for an extension of the indication for Velcade (bortezomib)
Hip_fracture_treatment
